Summary: Time-resolved fluoroimmunoassays were used for the detection of pancreatic group I and synovialtype group II phospholipases A 2 in sera of patients suffering from chronic renal failure before and after haemodialysis. The concentration of group I phospholipase A 2 was ten-fold higher in sera of uraemic patients than in healthy controls. There was no significant difference in the concentrations of group I phospholipase A 2 in serum before and after haemodialysis. The concentration of group II phospholipase A 2 was only marginally increased in sera of uraemic patients, compared with healthy controls. There was no significant difference in the concentrations of group II phospholipase A 2 before and after haemodialysis. The results indicate that the metabolism of group I phospholipase A 2 differs from that of group II phospholipase A 2 in chronic renal failure.
Introduction
Extracellular phospholipases A 2 J ) have been classified into two types: pancreatic group I phospholipase A 2 and synovial-type group II phospholipase A 2 on the basis of the primary structure of the enzyme protein. Group I phospholipases A 2 contain a cysteine at position 11 that forms a disulphide bridge with a cysteine at position 77, whereas group II phospholipases A 2 lack these cysteines and the corresponding disulphide bridge (1) . Group I phospholipase A 2 is secreted by pancreatic acinar cells as an enzymatically inactive proenzyme into the duodenum, where it is activated by trypsin (2, 3) . Increased concentrations of immunoreactive group I phospholipase A 2 have been found in sera of patients suffering from acute pancreatitis (4, 5) and pancreatic cancer (4). Increased ') Enzyme:
Phosphatide 2-acylhydrolase, phospholipase A 2 (EC 3.1.1.4) phospholipase A 2 catalytic activities and concentrations of group II phospholipase A 2 have been measured in serum in sepsis (6, 7) and in synovial fluid and serum in rheumatoid arthritis and osteoarthritis (8) . The source of the circulating group II phospholipase A 2 is unknown.
High activities and concentrations of pancreatic enzymes have been measured in peripheral blood samples of patients suffering from chronic renal failure (9, 10) . The catalytic activity of phospholipase A 2 is more than eight-fold above normal in uraemic plasma (11) . The concentration of group I phospholipase A 2 in serum is elevated in patients suffering from acute renal dysfunction (12) and chronic renal failure (13).
The purpose of the present study was to investigate the concentrations of pancreatic and non-pancreatic phospholipases A 2 by specific immunoassays for group I phospholipase A 2 (14) and group II phospholipase A 2 (7) in sera of patients suffering from chronic renal failure. Measurements were done on serum samples taken before and after haemodialysis and compared with values of healthy individuals.
Materials and Methods

Serum samples
Blood samples were taken immediately before and after haemodialysis from 10 patients (6 men and 4 women, average age 50 years; range 24-72 years) suffering from chronic renal failure (five patients had chronic nephritis, one had Wegner's granulomatosis, gout or malignant hypertension and two patients had chronic renal failure of unknown etiology). There were no clinical signs of pancreatic disease in these patients. Serum was separated and stored at -20 °C until assayed.
Reference material was collected from 20 healthy blood donors (6 men and 14 women, average age 37 years; range 33-40 years) for the group I phospholipase A 2 assay and from 27 blood donors (21 men and 6 women, average age 31 years; range 24-66 years) for the group II phospholipase A 2 assay, and treated identically to patient sera.
Apparatus
Microtitre plates were washed in a 12-well aspirating-washing device (Wellwash 4, Denley, Billingham, England) and incubated in a shaking device (Wellmix 3). Fluorescence was measured with an Arcus fluorometer (Wallac, Turku, Finland) equipped with an external computer. Data were handled with a MultiCalc data management software (Wallac).
Standards
Human pancreatic group I phospholipase A 2 and recombinant synovial-type group II phospholipase A 2 stock solutions were diluted with a time-resolved fluoroimmunoassay (TR-FIA) assay buffer (Wallac) to give five standard concentrations (0.25, 1.5, 9.0, 54 and 324 μg/l). Group I phospholipase A 2 was purified from human pancreas as described elsewhere (15) . Recombinant synovial-type group II phospholipase A 2 was prepared as described elsewhere (16) .
Time-resolved fluoroimmunoassay
Time-resolved fluoroimmunoassays for group I phospholipase A 2 and group II phospholipase A 2 were performed as described earlier (7, 14, respectively) .
Statistical analysis
Student's t-test was used unless the difference of variances of variables warranted the use of Mann-Whitney's U-test. Tests were performed by using the BMDP statistical software package.
Results
Group I phospholipase A 2
Patients suffering from chronic renal failure had tenfold increased group I phospholipase A 2 values compared with the reference group, both before and after haemodialysis ( fig. 1 ). The mean concentration of group I phospholipase A 2 in the reference group was 4.0 μ §/1 (range from 1. with chronic renal failure. The difference between the reference samples and the samples taken before and after haemodialysis was statistically significant (p < 0.00004). The difference between the samples taken before and after haemodialysis was not statistically significant (p = 0.832).
Group II phospholipase A 2
The mean concentration of group II phospholipase A 2 in the reference group was 5.0 μ §/1 (range from 2.1 μ §/1 to 25.3 μ §/1, η = 27). The mean concentration of group II phospholipase A 2 before haemodialysis was 7.6 μ §/1 (range from 3.3 μ^ to 20.4 μ^, η = 10) and after haemodialysis 8.8 μg/l (range from 3.6 μt o 25.5 μg/l) in patients with chronic renal failure. There was no significant difference between group II phospholipase A 2 values in patients with chronic renal failure before haemodialysis and in the reference group (p = 0.137, fig. 2 ). The difference between the concentrations of group II ATP phospholipase A 2 in samples taken after haemodialysis and those of the reference group was marginally significant (p = 0.046). The difference between the samples taken before and after haemodialysis was not significant (p = 0.641).
Discussion
The role of phospholipase A 2 in acute pancreatitis has been discussed extensively (4, 17, 18) . Recent findings indicate that non-pancreatic (synovial-type) group II phospholipase A 2 is responsible for the increased catalytic activity of phospholipase A 2 in serum in acute pancreatitis (19, 20) , as in other inflammatory diseases (6, 7, 21). Patients suffering from chronic renal failure had increased catalytic activities of phospholipase A 2 in plasma (11) and increased concentrations of group I phospholipase A 2 in serum as determined by a radioimmunoassay (13). Our results confirm these findings. There was a statistically significant, ten-fold increase in the concentrations of group I phospholipase A 2 in sera of patients with chronic renal failure compared with reference material from healthy individuals. The treatment of uraemia by haemodialysis did not change the concentrations of group I phospholipase A 2 in the sera of the present patients. Our findings also confirm that the activities of pancreatic enzymes in serum increase in patients with end-stage renal disease (10) and chronic renal failure without pancreatic disease (9) . There were no changes in the elevated amylase activities during haemodialysis in these patients. Our patients had advanced chronic renal failure, but no signs of pancreatic disease. Experimental observations on nephrectomized and intact rats indicate that group I phospholipase A 2 injected intravenously is eliminated from the circulation mainly by the kidneys (22) .
The elevated catalytic activity of phospholipase A 2 in serum is caused by an increase in the concentration of group II phospholipase A 2 in various inflammatory diseases (6, 7, 19 -21) . The concentration of group II phospholipase A 2 in sera of the present patients with chronic renal failure was similar to that in the samples of healthy individuals. Haemodialysis did not change the concentration of group II phospholipase A 2 . These findings suggest that group I and group II phospholipases A 2 are metabolized differently when their renal elimination from blood plasma is disturbed.
It can be concluded that the concentration of group I phospholipase A 2 is markedly increased in serum in chronic renal failure, whereas the concentration of group II phospholipase A 2 remains within the reference interval. Haemodialysis does not affect the concentrations of group I and group II phospholipases A 2 in serum in patients with chronic renal failure.
